XETR
MRK
Market cap65bUSD
Sep 17, Last price
131.45EUR
1D
-0.19%
1Q
-1.09%
Jan 2017
32.58%
Name
Merck KGaA
Chart & performance
P/E
22.80
P/S
2.82
EPS
5.77
Div yield, %
1.67%
Shrs. gr., 5y
—
Rev. gr., 5y
2.94%
Revenues
20.27b
-4.19%
Net income
2.51b
-9.79%
CFO
3.78b
-17.64%
Dividend
Apr 27, 20262.2 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Globally, MERCK Kommanditgesellschaft auf Aktien conducts operations across the healthcare, life science, and electronics sectors. The company is actively involved in the research, development, production, and commercialization of both pharmaceutical and biological prescription medications. These treatments target a range of medical conditions, including those in neurology, immunology, oncology, fertility, and cardiometabolic and endocrine disorders. Furthermore, its life science division furnishes essential products, instruments, and services to support research facilities, pharmaceutical and biotechnology manufacturing, and industrial as well as analytical testing laboratories. Within its electronics segment, MERCK supplies crucial materials for integrated circuits, liquid crystals, organic light-emitting diodes (OLEDs), photoresists, smart antenna systems, and liquid crystal glazing solutions. It also produces specialized effect pigments extensively utilized in applications such as automotive coatings, cosmetics, and various industrial and plastics manufacturing. MERCK maintains strategic partnerships with Pfizer Inc., has an agreement with Novartis AG, and holds license arrangements with Debiopharm International SA and MoonLake Immunotherapeutics AG. Established in 1668, the firm's headquarters are located in Darmstadt, Germany, and it operates as a subsidiary of E. Merck Kommanditgesellschaft.
Related entities
Parent
E. Merck KG
Subsidiaries (56)
MERCK SPECIALITIES PRIVATE LIMITED
Merck Ventures B.V.
MILLIPORE
Millipore International Holdings S.àr.l.
mo ke tou zi (zhong guo) you xian gong si
Ridgefield Acquisition
Sigma-Aldrich Chemie GmbH
SIGMA-ALDRICH COMPANY LIMITED
Sigma-Aldrich Production GmbH
Sigma-Aldrich Pte. Ltd.
Sigma-Aldrich Quimica, S. de R.L. de C.V.
Susonity Holdings LLC
Versum Materials Pacific B.V.
Versum Materials Technology LLC
xi ge ma ao de li qi (shang hai) mao yi you xian gong si
xi ge ma-a er de li qi (wu xi) sheng ming ke xue yu ji shu you xian gong si
Key people
Chairman of Executive Board and Chief Executive Officer · since 2016
Constantin Birnstiel
Head of Group Communications · since 2017
Isabel De Paoli
Chief Strategy Officer, Head of Communications · since 2016
Anke Schenkel
Head of Group Controlling & Risk Management · since 2017
Michaela Freifrau von Glenck
Independent Member of the Supervisory Board
Albrecht Merck
Independent Member of the Supervisory Board · since 2005
Independent Member of the Supervisory Board · since 2014
Juergen Glaser
Member of the Supervisory Board and Employee Representative · since 2019
Sascha Held
Member of the Supervisory Board, Employee Representative
Peter Emanuel Merck
Member of the Supervisory Board · since 2019
Alexander J. Putz
Independent Member of the Supervisory Board, Employee Representative · since 2014
Simon Thelen
Member of the Supervisory Board · since 2019
Headquarters & legal address
Frankfurter Straße 250
Darmstadt, HE 64293
DE
Darmstadt, HE 64293
DE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||